AI
The companies will combine their complementary pathology tools to leverage services for tech-enabled diagnostics, drug discovery and patient care.
The new capital boosts Olive’s valuation to $4 billion.
Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.
The startup's technology is now incorporated into Fujifilm's digital x-ray system, in addition to being used in Malaysian clinics.
The company has developed a line of products targeting the mammography space to enable early and accurate breast cancer detection.
Viome has adapted its technology to search for the presence of oral squamous cell carcinoma and oropharyngeal cancer in users’ saliva samples.
Alife also added Deena Shakir, a partner at Lux Capital, to its board of directors.
The new joint venture will leverage AI technology to create digital healthcare solutions for the employer and consumer markets.
The new algorithm allows for automated analysis of CT scans of patients with the condition.
The Oxehealth Vital Signs system is installed in a patient's hospital room, where it can spot-measure pulse, heart, respiratory and breathing rates with no physical contact.